These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 26480700

  • 21. Neutralising antibodies against interferon beta in multiple sclerosis.
    Antonelli G.
    Lancet; 2004 Jan 10; 363(9403):168; author reply 168-9. PubMed ID: 14726180
    [No Abstract] [Full Text] [Related]

  • 22. Long-term follow-up of clinical trials of multiple sclerosis therapies.
    Freedman MS.
    Neurology; 2011 Jan 04; 76(1 Suppl 1):S26-34. PubMed ID: 21205679
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Interferon-beta treatment for multiple sclerosis.
    Bermel RA, Rudick RA.
    Neurotherapeutics; 2007 Oct 04; 4(4):633-46. PubMed ID: 17920544
    [Abstract] [Full Text] [Related]

  • 28. Interferon-beta in multiple sclerosis. Can we control its costs?
    Madgwick T.
    Pharmacoeconomics; 1997 Oct 04; 12(4):499-501. PubMed ID: 10174315
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Bioavailability of interferon-beta in patients with multiple sclerosis - fishing for the surrogate.
    Kieseier BC, Hartung HP.
    Eur J Neurol; 2010 Mar 04; 17(3):344-5. PubMed ID: 20050905
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Does interferon beta therapy affect survival of multiple sclerosis patients?
    Kułakowska A, Drozdowski W.
    Neurol Neurochir Pol; 2014 Mar 04; 48(6):436-41. PubMed ID: 25482255
    [Abstract] [Full Text] [Related]

  • 37. Incidence of antibodies in cerebrospinal fluid of patients with multiple sclerosis treated with interferon beta.
    Villa AM, Videla C, Garcea O, Carballal G.
    Arq Neuropsiquiatr; 2009 Sep 04; 67(3B):900-1. PubMed ID: 19838526
    [No Abstract] [Full Text] [Related]

  • 38. Multiple sclerosis: monotherapy rules.
    Hauser SL, Josephson SA, Johnston SC.
    Ann Neurol; 2013 Mar 04; 73(3):A5-6. PubMed ID: 23596013
    [No Abstract] [Full Text] [Related]

  • 39. Interferon-beta treatment and the natural history of relapsing-remitting multiple sclerosis.
    Koch M, Mostert J, De Keyser J, Tremlett H, Filippini G.
    Ann Neurol; 2008 Jan 04; 63(1):125-6; author reply 126-7. PubMed ID: 17702024
    [No Abstract] [Full Text] [Related]

  • 40. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
    Kieseier BC, Hartung HP.
    Exp Neurol; 2007 Jan 04; 203(1):1-4. PubMed ID: 17069803
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.